NUVI 100% BUYS HUGE NEWS NUVI Requests Proposal from Nutriceutical Manufacturer
TORONTO, Nov. 18, 2013 /PRNewswire/ - EMO CAPITAL CORP (NUVI:OTCBB) - is excited to announce that the Company has requested a proposal from a USA based nutriceutical supplement manufacturer for production and packaging of its ME-4Free capsule.
The manufacturer was founded in 2003 and is a Federal Drug Agency (FDA) approved and a Good Manufacturing Practices (GMP) certified facility. All ingredients stocked by the manufacturer are United States Pharmacopeia (USP) grade, which is the official standards setting authority for all prescription and over-the-counter medicines, dietary supplements, and other healthcare products manufactured in the Unites States.
Concurrent with the production development, the Company will also be building a reliable distribution worldwide network, thereby positioning it with a firm position in the health care products industry.
Supplement sales reached $11.5 billion in US in 2012 and are expected to reach $15.5 billion by 2017. NUVI expects this growing market to strengthen demand for the ME-4Free capsules and other NUVI products.
About ME-4Free:
ME-4Free is a once-daily capsule for men that delivers a natural and effective method to maximize their sexual health by boosting testosterone levels. ME-4Free male enhancement pills are preferred by users looking for an alternative to prescription pills.
Forward-Looking Statements:
The statements by our officers, and other statements regarding optimism related to the business, expanding exploration and development activities and other statements in this press release are forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Such statements are based on current expectations, estimates and projections about the Company's business. Words such as expects, anticipates, intends, plans, believes, sees, estimates and variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and involve certain risks and uncertainties that are difficult to predict. Actual results could vary materially from the description contained herein due to many risk factors that affect the industry the Company operates in and other risk factors listed from time to time in the Company's Securities and Exchange Commission (SEC) filings under "risk factors" and elsewhere. The forward-looking statements contained in this press release speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this press release.
SOURCE EMO CAPITAL CORP
Copyright 2013 PR Newswire
TORONTO, Nov. 18, 2013 /PRNewswire/ - EMO CAPITAL CORP (NUVI:OTCBB) - is excited to announce that the Company has requested a proposal from a USA based nutriceutical supplement manufacturer for production and packaging of its ME-4Free capsule.
The manufacturer was founded in 2003 and is a Federal Drug Agency (FDA) approved and a Good Manufacturing Practices (GMP) certified facility. All ingredients stocked by the manufacturer are United States Pharmacopeia (USP) grade, which is the official standards setting authority for all prescription and over-the-counter medicines, dietary supplements, and other healthcare products manufactured in the Unites States.
Concurrent with the production development, the Company will also be building a reliable distribution worldwide network, thereby positioning it with a firm position in the health care products industry.
Supplement sales reached $11.5 billion in US in 2012 and are expected to reach $15.5 billion by 2017. NUVI expects this growing market to strengthen demand for the ME-4Free capsules and other NUVI products.
About ME-4Free:
ME-4Free is a once-daily capsule for men that delivers a natural and effective method to maximize their sexual health by boosting testosterone levels. ME-4Free male enhancement pills are preferred by users looking for an alternative to prescription pills.
Forward-Looking Statements:
The statements by our officers, and other statements regarding optimism related to the business, expanding exploration and development activities and other statements in this press release are forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Such statements are based on current expectations, estimates and projections about the Company's business. Words such as expects, anticipates, intends, plans, believes, sees, estimates and variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and involve certain risks and uncertainties that are difficult to predict. Actual results could vary materially from the description contained herein due to many risk factors that affect the industry the Company operates in and other risk factors listed from time to time in the Company's Securities and Exchange Commission (SEC) filings under "risk factors" and elsewhere. The forward-looking statements contained in this press release speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this press release.
SOURCE EMO CAPITAL CORP
Copyright 2013 PR Newswire
